Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

References

• Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–299. doi: 10.1002/ijc.21183. PMID:15900604
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol 2016; 893:1–19. doi: 10.1007/978-3-319-24223-1_1. PMID:26667336
   PubMed Web of Science ®Google Scholar
• Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119–50. doi: 10.1146/annurev.pathol.1.110304.100224. PMID:18039110
   PubMed Web of Science ®Google Scholar
• Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44. doi: 10.1200/JCO.2008.18.9068. PMID:19470939
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517. doi: 10.1146/annurev.immunol.021908.132710. PMID:19132915
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–98. doi: 10.1056/NEJMra0707449. PMID:19710487
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28(1):29–39. doi: 10.1016/j.immuni.2007.11.016. PMID:18164222
   PubMed Web of Science ®Google Scholar
• Dong C. Targeting Th17 cells in immune diseases. Cell Res. 2014;24(8):901–903. doi: 10.1038/cr.2014.92. PMID:25022899
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang J, Horwitz DA. Cutting Edge: Foxp3+CD4+CD25+ Regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6. J Immunol. 2008;180:7112–7116. doi: 10.4049/jimmunol.180.11.7112. PMID:18490709
   PubMed Web of Science ®Google Scholar
• Chen Z, Lin F, Gao Y, Li Z, Zhang J, Xing Y, Deng Z, Yao Z, Tsun A, Li B. FOXP3 and RORγt: Transcriptional regulation of Treg and Th17. Int Immunopharmacol. 2011;11(5):536–42. doi: 10.1016/j.intimp.2010.11.008. PMID:21081189
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17- mediated tumour growth. Nature. 2012;491:254–8. doi: 10.1038/nature11465. PMID:23034650
   PubMed Web of Science ®Google Scholar
• Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S. A role for T-bet-mediated tumour immune surveillance in anti–IL-17A treatment of lung cancer. Nat Commun. 2011;2:600. doi: 10.1038/ncomms1609. PMID:22186896
   PubMed Web of Science ®Google Scholar
• Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36:362–73. doi: 10.1016/j.immuni.2011.12.019. PMID:22406269
   PubMed Web of Science ®Google Scholar
• Du JW, Xu KY, Fang LY, Qi XL. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep. 2012;6:1099–102. doi: 10.3892/mmr.2012.1036. PMID:22922996
   PubMed Web of Science ®Google Scholar
• De Simone V, Pallone F, Monteleone G, Stolfi C. Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology. 2013;2(12):e26617. doi: 10.4161/onci.26617. PMID:2449854
   PubMed Web of Science ®Google Scholar
• Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X, Chen W, Cheng P, Wang T, Chen N, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32(6):1332–9. doi: 10.1007/s10875-012-9718-8. PMID:22760549
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. doi: 10.1038/ni1254. PMID:16200070
   PubMed Web of Science ®Google Scholar
• Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus P, Lomberk G, et al. IL-17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Res. 2015;75(22):4852–62. doi: 10.1158/0008-5472.CAN-15-0896. PMID:26404002</bib>
   PubMedGoogle Scholar
• Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early Colorectal Tumorigenesis. Immunity. 2014;41(6):1052–63. doi: 10.1016/j.immuni.2014.11.009. PMID:25526314
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang CJ, Martin BN, Bulek K, Kang Z, Zhao J, Bian G, Carman JA, Gao J, Dongre A, et al. IL-17 induced NOTCH1 activation in oligodendrocyte progenitor cells enhances proliferation and inflammatory gene expression. Nat Commun 2017;8:15508. doi: 10.1038/ncomms15508. PMID:28561022
   PubMed Web of Science ®Google Scholar
• Wang R, Ye X, Bhattacharya R, Boulbes DR, Fan F, Xia L, Ellis LM. A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via Notch1 Signaling. Stem Cells Transl Med 2016; 5(3):331–8. doi: 10.5966/sctm.2015-0168. PMID:26744411
   PubMed Web of Science ®Google Scholar
• Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, et al. Immune classification with cytotoxic CD8 and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. Oncoimmunology. 2017;6(6):e1321186. doi: 10.1080/2162402X.2017.1321186. PMID:28680758
   PubMed Web of Science ®Google Scholar
• Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010;29:3313–23. doi: 10.1038/onc.2010.109. PMID:20400974
   PubMed Web of Science ®Google Scholar
• Chen D, Hu Q, Mao C, Jiao Z, Wang S, Yu L, Xu Y, Dai D, Yin L, Xu H. Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. Cell Immunol. 2012;272:166–174. doi: 10.1016/j.cellimm.2011.10.015. PMID:22082565
   PubMed Web of Science ®Google Scholar
• Hu J, Mao Y, Li M, Lu Y. The profile of Th17 subset in glioma. Int. Immunopharmacol. 2011;11:1173–1179. doi: 10.1016/j.intimp.2011.03.015. PMID:21473956
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–52. doi: 10.1146/annurev.immunol.25.022106.141557. PMID:17201677
   PubMed Web of Science ®Google Scholar
• Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467–76. doi: 10.1016/j.immuni.2004.08.018. PMID:15485625
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs. 2009;10:543–9. PMID:19513943
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Smyth MJ, Teng MW. Does IL-17 suppress tumor growth? Blood. 2010;115:2554–5. doi: 10.1182/blood-2009-11-254607. PMID:20339108
   PubMed Web of Science ®Google Scholar
• Ji Y, Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother. 2010;59:979–87. doi: 10.1007/s00262-010-0849-6. PMID:20352428
   PubMed Web of Science ®Google Scholar
• Vizio B, Novarino A, Giacobino A, Cristiano C, Prati A, Ciuffreda L, Montrucchio G, Bellone G. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med. 2012;4:70–78. doi: 10.3892/etm.2012.553. PMID: 23060925
   PubMed Web of Science ®Google Scholar
• Yamada, Y., Saito, H., and Ikeguchi, M. Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res 2012; 178:685–691. doi: 10.1016/j.jss.2012.07.055. PMID: 22940035
   PubMed Web of Science ®Google Scholar
• Benevides L, da Fonseca DM, Donate PB, Tiezzi DG, De Carvalho DD, de Andrade JM, Martins GA, Silva JS. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 2015;75(18):3788–99. doi: 10.1158/0008-5472.CAN-15-0054. PMID:26208902
   PubMed Web of Science ®Google Scholar
• Reppert S, Boross I, Koslowski M, Türeci Ö, Koch S, Lehr HA, Finotto S. A role for T-bet-mediated tumour immune surveillance in anti–IL-17A treatment of lung cancer. Nat Commun. 2011;2:600. doi: 10.1038/ncomms1609. PMID:22186896
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263–71. doi: 10.1158/0008-5472.CAN-10-2907. PMID:21303976
   PubMed Web of Science ®Google Scholar
• Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett. 2005;98:189–193. doi: 10.1016/j.imlet.2004.11.012. PMID:15860217
   PubMed Web of Science ®Google Scholar
• Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 2004;93:39–43. doi: 10.1016/j.imlet.2004.01.014. PMID:15134897
   PubMed Web of Science ®Google Scholar
• Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer. 2011;10:150. doi: 10.1186/1476-4598-10-150. PMID: 22171994
   PubMed Web of Science ®Google Scholar
• Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43:1518–28. doi: 10.1002/eji.201242951. PMID:23529839
   PubMed Web of Science ®Google Scholar
• Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. 2015;34(2):165–76. doi: 10.1038/onc.2013.537. PMID:24362529
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206(7):1457–64. doi: 10.1084/jem.20090207. PMID:19564351
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 2010;70:10112–10120. doi: 10.1158/0008-5472.CAN-10-0775. PMID:21159633
   PubMed Web of Science ®Google Scholar
• Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15(4):283–93. doi: 10.1016/j.ccr.2009.02.015. PMID:19345327
   PubMed Web of Science ®Google Scholar
• Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem. 2013;288(36):26167–76. doi: 10.1074/jbc.M113.477950. PMID:23902772
   PubMed Web of Science ®Google Scholar
• Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72(Suppl2), ii116–ii123. doi: 10.1136/annrheumdis-2012-202371. PMID:23253932
   PubMedGoogle Scholar
• Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 2015; 75(13):1341–53. doi: 10.1002/pros.23015. PMID:25970160
   PubMed Web of Science ®Google Scholar
• Wang F, Li H, Qiao JO. 1-O-acetylbritannilactone combined with gemcitabine elicits growth inhibition and apoptosis in A549 human non small cell lung cancer cells. Mol Med Rep. 2015;12(4):5568–5572. doi: 10.3892/mmr.2015.4042. PMID:26151622
   PubMed Web of Science ®Google Scholar
• Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, et al. A Phase I First-in-human study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin Cancer Res. 2015;21(12):2695–2703. doi: 10.1158/1078-0432.CCR-14-2797. PMID:25724527
   PubMed Web of Science ®Google Scholar
• Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, Yue D, Chen X, Ping Y, Huang L, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages. Int J Cancer. 2016;139(10):2261–2269. doi: 10.1002/ijc.30289. PMID:27459735
   PubMed Web of Science ®Google Scholar
• Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N, et al. Macrophage-derived Wnt opposes notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med. 2012;18:572–579. doi: 10.1038/nm.2667. PMID:22388089
   PubMed Web of Science ®Google Scholar